Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors

医学 内科学 多发性骨髓瘤 肺栓塞 癌症 深静脉 血栓形成 置信区间 单变量分析 化疗 外科 静脉血栓形成 胃肠病学 多元分析
作者
Ramón Lecumberri,Pedro Ruiz-Artacho,Inna Tzoran,Benjamin Brenner,Dominique Farge-Bancel,Cihan Ay,Vladimir Rosa,Iria Francisco,Luis Hernández-Blasco,Javier Trujillo-Santos,Manuel Monreal
出处
期刊:Thrombosis and Haemostasis [Georg Thieme Verlag KG]
卷期号:122 (09): 1594-1602 被引量:4
标识
DOI:10.1055/a-1777-4006
摘要

Abstract Background The natural history of patients with hematologic cancer and venous thromboembolism (VTE) has not been consistently evaluated. We aimed to compare the rates of symptomatic recurrent VTE, major bleeding, or death during anticoagulant therapy in patients with VTE associated with hematologic versus solid cancers. Methods Consecutive patients with active cancer recruited in RIETE were evaluated. Their baseline characteristics, treatments, and outcomes during the course of anticoagulation were compared. Univariate and multivariate competing-risk analyses were performed. Results As of December 2020, 16,694 patients with cancer and VTE were recruited. Of these, 1,062 (6.4%) had hematologic cancers. Hematologic patients were less likely to initially present with pulmonary embolism (46 vs. 55%) and more likely with upper extremity deep vein thrombosis (25 vs. 18%). They also were more likely to have severe thrombocytopenia at baseline (5.6 vs. 0.7%) or to receive chemotherapy (67 vs. 41%). During the course of anticoagulation (median, 150 vs. 127 days), 1,071 patients (6.4%) developed VTE recurrences, 806 (4.8%) suffered major bleeding, and 4,136 (24.8%) died. Patients with hematologic cancers had lower rates of recurrent VTE (rate ratio [RR]: 0.73; 95% confidence interval [CI]: 0.56–0.95), major bleeding (RR: 0.72; 95% CI: 0.53–0.98), or all-cause death (RR: 0.49; 95% CI: 0.41–0.57) than those with solid cancers. Patients with multiple myeloma showed the best outcomes. Conclusion Patients with hematologic cancers, particularly multiple myeloma, and VTE had better outcomes than those with solid cancers. These findings are relevant for the interpretation of previous clinical trials and the design of future studies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光子完成签到,获得积分10
2秒前
yjjslbyfbgfwz完成签到,获得积分10
4秒前
5秒前
Bottle完成签到,获得积分10
6秒前
悟空完成签到,获得积分10
8秒前
yjjslbyfbgfwz发布了新的文献求助10
9秒前
14秒前
哭泣初夏完成签到 ,获得积分10
15秒前
gao完成签到,获得积分10
17秒前
TKMY完成签到,获得积分10
17秒前
太阳alright发布了新的文献求助10
17秒前
18秒前
Robert完成签到,获得积分10
24秒前
天天快乐应助yjjslbyfbgfwz采纳,获得10
25秒前
太阳alright完成签到,获得积分10
27秒前
清逸之风发布了新的文献求助10
27秒前
30秒前
35秒前
凤凰应助科研通管家采纳,获得30
35秒前
35秒前
研友_VZG7GZ应助科研通管家采纳,获得10
35秒前
Qixiner应助科研通管家采纳,获得10
35秒前
脑洞疼应助科研通管家采纳,获得10
35秒前
FashionBoy应助科研通管家采纳,获得10
35秒前
深情安青应助科研通管家采纳,获得10
35秒前
zzpj发布了新的文献求助10
35秒前
科目三应助科研通管家采纳,获得10
35秒前
36秒前
Leonardi应助gao采纳,获得10
36秒前
乐乐应助漂泊采纳,获得10
37秒前
亓亓发布了新的文献求助10
38秒前
Owen应助七宝大当家采纳,获得10
38秒前
39秒前
王梓磬发布了新的文献求助10
40秒前
不安的嘉懿完成签到 ,获得积分10
43秒前
烟花应助guojingjing采纳,获得10
43秒前
大鹏发布了新的文献求助10
43秒前
坚强的广山应助烟雨客采纳,获得10
44秒前
弈心完成签到 ,获得积分10
45秒前
46秒前
高分求助中
请在求助之前详细阅读求助说明 20000
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The Three Stars Each: The Astrolabes and Related Texts 500
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 500
Additive Manufacturing Design and Applications 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2464830
求助须知:如何正确求助?哪些是违规求助? 2133256
关于积分的说明 5435544
捐赠科研通 1859140
什么是DOI,文献DOI怎么找? 924652
版权声明 562561
科研通“疑难数据库(出版商)”最低求助积分说明 494693